A Study to Evaluate Pembrolizumab in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein / Programmed Cell Death Ligand 1 Treatment
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with pembrolizumab, with or without chemotherapy, for the treatment of participants